 |
|
These slide decks cover the topic of Lung Cancer/Head and Neck Cancer:
Incorporating genomic tests in decision making
Fadlo Khuri, MD
Targeted therapy in lung cancer
Roman Perez-Soler, MD
Multidisciplinary approach to lung cancer
Thomas D'Amico, MD
Tailoring front-line therapy for advanced non-small cell lung cancer (NSCLC)
Roman Perez-Soler, MD
Second-line therapy for advanced NSCLC
Merrill Kies, MD
Is the role of surgery decreasing in head and neck cancer?
Fadlo Khuri, MD, and W. Jarrard Goodwin, MD, FACS
Should every responding or stable patient with advanced NSCLC be offered maintenance therapy?
Roman Perez-Soler, MD, and Merrill Kies, MD
|
 |
|
These slide decks cover the topic of Gastrointestinal (GI) Cancer:
Incorporating genomic tests in decision making
Ramesh Ramanathan, MD
Targeted therapy in GI cancers
Zev Wainberg, MD, MSc
Multidisciplinary approach to GI cancer
Bruce Minsky, MD
Metastatic colorectal cancer
Zev Wainberg, MD, MSc
Metastatic gastric cancer
Ramesh Ramanathan, MD
Should all gastric cancer patients have HER2 testing?
Ramesh Ramanathan, MD, and Zev Wainberg, MD, MSc
|
 |
|
These slide decks cover the topic of Breast Cancer:
Incorporating genomic tests in decision making
Susana Campos, MD, MPH
Targeted therapy in breast cancer
Mary Cianfrocca, DO
Multidisciplinary approach to breast cancer
Terry Mamounas, MD, MPH, FACS
HER2-positive metastatic breast cancer
Susana Campos, MD, MPH
Recurrent triple-negative breast cancer
Ruth O'Regan, MD
Should every patient with a positive sentinel lymph node undergo axillary dissection?
Terry Mamounas, MD, MPH, FACS, and Ruth O'Regan, MD
Should all postmenopausal HER2-positive/ER-positive patients receive combination of an aromatase inhibitor and HER2 blockade?
Susana Campos, MD, MPH, and Ruth O'Regan, MD
|
 |
|
These slide decks cover the topic of Prostate Cancer:
Targeted therapy in prostate cancer
Philip Kantoff, MD
Multidisciplinary approach to prostate cancer
Mark Soloway, MD
Hormone-responsive prostate cancer (HRPC)
Philip Kantoff, MD
Castration-resistant prostate cancer
Matthew R. Smith, MD, PhD
Are all taxanes equivalent in the treatment of HRPC?
Matthew R. Smith, MD, PhD, and Robert Fine, MD
Is immunotherapy the choice systemic therapy for the future?
Philip Kantoff, MD, and Mark Soloway, MD
|
|
|
